Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results

  • Cristina NanniEmail author
  • Riccardo Schiavina
  • Stefano Boschi
  • Valentina Ambrosini
  • Cinzia Pettinato
  • Eugenio Brunocilla
  • Giuseppe Martorana
  • Stefano Fanti
Original Article



We assessed the rate of detection rate of recurrent prostate cancer by PET/CT using anti-3-18F-FACBC, a new synthetic amino acid, in comparison to that using 11C-choline as part of an ongoing prospective single-centre study.


Included in the study were 15 patients with biochemical relapse after initial radical treatment of prostate cancer. All the patients underwent anti-3-18F-FACBC PET/CT and 11C-choline PET/CT within a 7-day period. The detection rates using the two compounds were determined and the target–to-background ratios (TBR) of each lesion are reported.


No adverse reactions to anti-3-18F-FACBC PET/CT were noted. On a patient basis, 11C-choline PET/CT was positive in 3 patients and negative in 12 (detection rate 20 %), and anti-3-18F-FACBC PET/CT was positive in 6 patients and negative in 9 (detection rate 40 %). On a lesion basis, 11C-choline detected 6 lesions (4 bone, 1 lymph node, 1 local relapse), and anti-3-18F-FACBC detected 11 lesions (5 bone, 5 lymph node, 1 local relapse). All 11C-choline-positive lesions were also identified by anti-3-18F-FACBC PET/CT. The TBR of anti-3-18F-FACBC was greater than that of 11C-choline in 8/11 lesions, as were image quality and contrast.


Our preliminary results indicate that anti-3-18F-FACBC may be superior to 11C-choline for the identification of disease recurrence in the setting of biochemical failure. Further studies are required to assess efficacy of anti-3-18F-FACBC in a larger series of prostate cancer patients.


ANTI-3-18F-FACBC 11C-Choline PET/CT Prostate cancer PSA 


Conflicts of interest



  1. 1.
    Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331–8.PubMedGoogle Scholar
  2. 2.
    Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18 FFACBC in humans. J Nucl Med. 2007;48(6):1017–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39(1):109–19.PubMedCrossRefGoogle Scholar
  4. 4.
    Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52(5):822–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1- amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56–63.PubMedGoogle Scholar
  6. 6.
    Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [(18)F]fluciclovine (anti-[ (18)F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(3):394–402.PubMedCrossRefGoogle Scholar
  7. 7.
    Schuster DM, Savir-Baruch D, Nieh P, Master VA, Halkar RK, Rossi PJ, et al. Detection of recurrent prostate carcinoma with anti-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology. 2011;259:852–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184(3):938–43.PubMedCrossRefGoogle Scholar
  9. 9.
    McConathy J, Voll RJ, Yu W, Crowe RJ, Goodman MM. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58(6):657–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Pascali C, Bogni A, Itawa R, Cambiè M, Bombardieri E. [11C]Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm. 2000;49:195–203.CrossRefGoogle Scholar
  11. 11.
    Iatrou M, Ross SG, Manjeshwar RM, Stearns CW. A fully 3D iterative image reconstruction algorithm incorporating data corrections. Nuclear Science Symposium Conference Record, 2004, IEEE. 2004;4:2493–7.Google Scholar
  12. 12.
    Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54(5):884–90.PubMedCrossRefGoogle Scholar
  13. 13.
    Beissert M, Lorenz R, Gerharz EW. Rational imaging in locally advanced prostate cancer. Urologe A. 2008;47(11):1405–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Reske SN, Blumstein NM, Glatting G. PET and PET/CT in relapsing prostate carcinoma. Urologe A. 2006;45(10):1240, 1242–4, 1246–8, 1250.PubMedCrossRefGoogle Scholar
  15. 15.
    Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol. 2011;11:14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Cristina Nanni
    • 1
    Email author
  • Riccardo Schiavina
    • 2
  • Stefano Boschi
    • 1
  • Valentina Ambrosini
    • 2
  • Cinzia Pettinato
    • 3
  • Eugenio Brunocilla
    • 2
  • Giuseppe Martorana
    • 2
  • Stefano Fanti
    • 2
  1. 1.OU Nuclear MedicineAzienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-MalpighiBolognaItaly
  2. 2.OU UrologyAzienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-MalpighiBolognaItaly
  3. 3.OU Medical PhysicsAzienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-MalpighiBolognaItaly

Personalised recommendations